Apogee Therapeutics, Inc. research snapshot
APGE AI stock analysis reads Apogee Therapeutics as a merger-arbitrage situation approaching a defined shareholder vote rather than a normal standalone biotech valuation. AbbVie announced on June 22, 2026 an all-cash acquisition of Apogee for $135.11 per share under a merger agreement dated June 18, 2026, implying about $10.9 billion of equity value. Apogee filed a definitive proxy on July 13, 2026 and scheduled a virtual special meeting of stockholders for August 11, 2026; holders of a majority of the roughly 61.9 million voting shares outstanding at the July 10 record date must approve the merger, and closing also depends on HSR and other regulatory conditions. APGE closed at $134.09 on July 31, leaving a gross spread of about $1.02 per share, or roughly 0.8%, before time, taxes, and deal risk. The company still has no product revenue, reported a $255.8 million 2025 net loss and a $74.1 million first quarter 2026 net loss, and is advancing zumilokibart toward a Phase 3 program in atopic dermatitis after positive Phase 2 Part B 16-week data. This APGE AI stock analysis is informational only and is not investment advice.
Current price
$134.09 at the July 31, 2026 Nasdaq close
Market cap
$10.07 billion using 75.08 million shares outstanding, matching the StockAnalysis snapshot
AI score
63 / 100
Rating
Merger-arbitrage biotech with a signed AbbVie cash acquisition, a definitive proxy, a scheduled August 11 stockholder vote, no product revenue, and a clinical pipeline entering Phase 3
Trend status
Event-driven and within about 0.8% of the $135.11 merger consideration, with the August 11 special meeting as the next decision point
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Apogee is a focused clinical-stage biotech developing engineered antibodies for atopic dermatitis, asthma, eosinophilic esophagitis, COPD, and related inflammatory diseases. It has no product sales yet. | High |
| Moat | Potential advantages include long-acting antibody engineering, clinical data, licensed target assets, and a multi-indication pipeline. Commercial switching costs, brand power, and network effects are not established. | Medium |
| Management | CEO Michael Henderson and the board advanced the pipeline, raised capital, signed a Blackstone financing collaboration, negotiated the AbbVie transaction, and unanimously recommended stockholder approval in the definitive proxy. The live test is whether the board protects closing certainty and shareholder value through the August 11 vote and closing. | Medium-high |
| Financial trend | Apogee generated no product revenue. Net loss grew from $84.0 million in 2023 to $182.1 million in 2024 and $255.8 million in 2025, while 2025 operating cash use was $227.45 million and first quarter 2026 operating cash use was $55.6 million. | High |
| Valuation | At $134.09, APGE trades about 0.8% below the $135.11 cash merger price. PE, PS, and P/FCF are not useful positive operating multiples because earnings, revenue, and free cash flow are negative or absent. | High |
| Technical trend | The stock was within about 0.8% of its $135.11 deal ceiling and near the $134.46 52-week high, above the August 2 snapshot 50-day average of $112.77 and 200-day average of $82.93, with RSI at 78.56. These signals describe the deal gap, not a normal operating uptrend. | Medium |
| Risk level | Risk is high for standalone equity holders and medium-high for merger-arbitrage exposure because the August 11 vote, antitrust or other regulatory clearance, timing, deal termination, and a standalone repricing remain possible. | High |
| AI confidence | Data confidence is high for disclosed facts. Outcome confidence is lower because the value still depends on the pending vote, regulatory review, and a future transaction close. | High data confidence |
| Investment certainty | The contractual cash reference and definitive proxy improve visibility, but APGE is not a low-risk cash equivalent. The spread compensates for time and closing uncertainty, and the downside could be material if the merger breaks. | Low to moderate |
APGE AI stock forecast
The APGE AI stock forecast is a transaction and standalone-risk framework, not a price promise. The signed deal provides a $135.11 cash reference and the definitive proxy schedules an August 11, 2026 vote, but a conventional three-year EPS model is not decision-useful because APGE has no product revenue and negative EPS. The ranges below reflect possible market outcomes around closing, a superior proposal, or a broken deal.
$135.11 to $140
More likely if stockholders approve the merger on August 11, regulatory clearances are obtained on schedule, and the deal closes in the third quarter of 2026, or if a credible superior proposal improves the cash consideration. The contractual deal price limits ordinary upside unless terms change.
$133.50 to $135.11
More likely if the merger remains on track but time value, closing uncertainty, and market liquidity keep APGE below the $135.11 consideration until the transaction closes. The gross spread is not a guaranteed return.
$60 to $100
More likely if the merger is rejected, terminated, blocked, materially delayed, or renegotiated lower. The standalone stock could reprice toward its pre-announcement range while investors reassess the clinical pipeline, cash burn, and future financing needs.
APGE AI technical analysis
APGE AI technical analysis is dominated by the AbbVie deal. APGE closed at $134.09 on July 31, 2026, about 0.8% below the $135.11 cash consideration and near the $134.46 52-week high. StockAnalysis reported a 50-day moving average of $112.77, a 200-day moving average of $82.93, RSI of 78.56, and 20-day average volume of about 1.17 million shares in its August 2 snapshot. These indicators are distorted by the merger gap and should not be read as independent evidence of drug approval or business value.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $134.09 | StockAnalysis closing quote for July 31, 2026. The after-hours reference was $134.13 in the same snapshot. |
| Immediate support | $133.00 to $133.82 | The recent post-announcement trading area around the July close. A break can reflect spread widening, not necessarily a change in clinical fundamentals. |
| Deeper standalone reference | $84 to $91 | The June 3 to June 18 pre-deal trading area in StockAnalysis history. It is a risk reference if the transaction fails, not a forecast target. |
| Near resistance | $134.46 | The reported 52-week high in the July 31 StockAnalysis data. Price discovery above this level would require a changed deal or a new catalyst. |
| Merger consideration | $135.11 | Cash per share under the announced AbbVie merger agreement. It is the principal price ceiling while the current terms remain in place. |
| Moving averages | 50-day $112.77; 200-day $82.93 | StockAnalysis statistics snapshot last updated August 2, 2026. Both averages lag the June 22 transaction gap. |
| Momentum | RSI 78.56 in the August 2 snapshot | The high RSI reflects the cash-deal repricing. Overbought readings do not resolve the probability of the August 11 vote or closing. |
| Volume | 20-day average about 1.17 million; June 22 volume 61.7 million | The transaction announcement produced a large volume spike, while later volume reflects merger-arbitrage positioning. |
| Volatility | 52-week range $34.34 to $134.46 | The wide range captures both standalone clinical-stage biotech risk and the later merger repricing. |
| Invalidation | Deal termination, failed vote, regulatory block, or changed consideration | A close below support alone widens the spread. The merger thesis is fundamentally invalidated by the transaction conditions, not by one technical candle. |
APGE AI trading strategy
The APGE AI trading strategy below is a non-personal research framework for a merger-arbitrage stock approaching a shareholder vote. It should be paired with the definitive proxy, live filings, the August 11 meeting result, the closing calendar, and a risk limit that can absorb a large standalone repricing. It is not investment advice.
Do not interpret a move above $135.11 as a normal breakout while the current agreement remains unchanged. A sustained move above the deal price would need a formal higher proposal, revised consideration, or another disclosed event before it can be treated as confirmation.
Avoid chasing a price above the contractual consideration without verifying the filing and the new terms. A close below $133.00 should trigger a review of spread, timing, and deal headlines rather than an automatic entry or exit.
Monitor the $133.00 to $133.50 area only when the merger agreement, board recommendation, regulatory process, and stockholder vote remain unchanged. The spread can widen on liquidity or timing without changing the underlying terms.
A wider spread is not automatically cheap. Recalculate expected value after taxes, time to close, vote risk, regulatory risk, termination fees, and the potential $60 to $100 standalone repricing case.
Track the August 11, 2026 special meeting and vote results, regulatory clearances such as HSR, the December 18, 2026 initial outside date and possible extensions to June 18, 2027, the $381.3 million termination fees, and any new APG777 or APG279 clinical disclosure.
Reduce confidence if AbbVie or Apogee changes the recommendation, a closing condition becomes doubtful, antitrust review expands, the agreement is terminated, or clinical data materially changes the standalone value.
Investment research summary
Apogee is trying to turn engineered, long-acting antibodies into medicines for large inflammatory and immunology markets. Zumilokibart targets IL-13 and is being developed first in atopic dermatitis, with asthma and eosinophilic esophagitis expansion plans. Customers do not pay Apogee yet because there are no approved commercial products.
The potential moat is a combination of antibody engineering, dosing convenience, clinical evidence, licensed target biology, and a pipeline that can reuse development knowledge across indications. There are no proven commercial switching costs or network effects, and established therapies such as Dupixent create a high bar for efficacy, safety, dosing, and reimbursement.
The thesis fails if the AbbVie merger does not close, the August 11 vote fails or is delayed beyond the market tolerance for the spread, or the standalone pipeline loses value through weak efficacy, safety, manufacturing, regulatory, competitive, or reimbursement outcomes. A failed transaction could expose shareholders to the company negative cash flow and future capital needs.
Michael Henderson is chief executive officer and Jane Pritchett Henderson is chief financial officer. The company raised equity, signed up to $1.3 billion of Blackstone financing that includes a synthetic royalty and potential debt, and then agreed to sell to AbbVie. The board unanimously recommended approval in the definitive proxy, and the key capital-allocation question is how the transaction handles existing financing obligations and whether shareholders receive the agreed cash consideration.
Inflammatory and immunology markets have durable medical need and large patient populations, but they are crowded and competitive. Long-acting dosing can matter to patients and payers, yet clinical differentiation must survive Phase 3 testing, regulatory review, manufacturing scale-up, treatment guidelines, and competition from established and emerging therapies. Positive Phase 2 Part B data support a Phase 3 plan, but the AbbVie agreement is evidence of strategic value, not proof of commercial success.
At $134.09, the stock is priced mainly against the $135.11 cash merger consideration, not against current revenue or earnings. Goldman Sachs derived an implied equity range of $126.05 to $149.30 per share using illustrative premiums, while Jefferies discounted cash flow analysis produced $98.90 to $119.20 per share, below the merger price; those analyses are not guarantees of a standalone floor. The practical margin of safety is the spread after time and closing risk, while the main downside is the gap to standalone value if the deal breaks.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| APGE latest completed-session price | $134.09 close on July 31, 2026; $134.13 after hours in the same snapshot | StockAnalysis overview and history | August 3, 2026 |
| Market capitalization and shares | $10.07 billion market cap and 75.08 million shares outstanding; $134.09 x 75.08 million calculates to $10.07 billion with 0.03% variance | StockAnalysis and Pineify financial_rigor.py | August 3, 2026 |
| Product revenue | No product revenue to date. Apogee says it does not expect product-sale revenue for several years, if at all, unless development succeeds and products receive approval. | Apogee 2025 Form 10-K and StockAnalysis financials | August 3, 2026 |
| Three-year expense and loss trend | Net loss was $84.0M in 2023, $182.1M in 2024, and $255.8M in 2025. R&D expense rose from $68.4M to $167.9M to $214.7M across those years. | Apogee 2025 Form 10-K and StockAnalysis financials | August 3, 2026 |
| 2025 cash flow | Operating cash use was $227.45M in the 10-K; StockAnalysis reports $232.60M free cash flow. The difference reflects cash flow and capex presentation. | Apogee 2025 Form 10-K and StockAnalysis financials | August 3, 2026 |
| Q1 2026 financial update | Net loss was $74.1M, R&D expense was $60.8M, G&A expense was $22.0M, and operating cash use was $55.6M for the quarter ended March 31, 2026. | Apogee Q1 2026 Form 10-Q and results release | August 3, 2026 |
| Liquidity | Cash, cash equivalents, marketable securities, and long-term marketable securities totaled about $1.3B at March 31, 2026. StockAnalysis separately reports $1.06B cash and equivalents in its August snapshot, so the line-item scopes are not identical. | Apogee Q1 2026 results release and StockAnalysis statistics | August 3, 2026 |
| APEX Phase 2 Part B 16-week results | Announced May 27, 2026. The trial met its primary endpoint; Week 16 EASI-75 was 61.6% on high dose, 65.9% on mid dose, 50.5% on low dose, and 23.4% on placebo, with p<0.001 for each active arm versus placebo. | Apogee May 27, 2026 8-K and press release | August 3, 2026 |
| Pipeline progress | APEX Phase 2 Part A 52-week data showed durable maintenance in atopic dermatitis; Phase 1b asthma data were positive; Phase 3 initiation in atopic dermatitis is expected later in 2026; APG279 was fully enrolled at 86 patients with interim 24-week data expected in the second half of 2026. | Apogee Q1 2026 results release | August 3, 2026 |
| Blackstone financing | Up to $1.3B of flexible capital. The revenue share agreement provides Tranche 1 funding of $100M, Tranche 2 funding of $100M, Tranche 3 funding of $200M, and Tranche 4 funding of $250M to $400M tied to Phase 3 enrollment, positive readouts, and FDA approval, with tiered royalties on future zumilokibart sales. | Apogee May 27, 2026 8-K and Blackstone release | August 3, 2026 |
| AbbVie merger consideration | AbbVie agreed to acquire Apogee for $135.11 per share in cash, implying about $10.9B of equity value. The merger agreement is dated June 18, 2026, and closing is expected in the third quarter of 2026 subject to conditions. | Apogee definitive proxy and June 22, 2026 announcement | August 3, 2026 |
| Special meeting and vote | Apogee filed a definitive proxy on July 13, 2026 and scheduled a virtual special meeting for August 11, 2026. The record date is July 10, 2026; about 61.9 million voting shares are entitled to vote and a majority of the outstanding voting shares is required for approval. The board unanimously recommends a FOR vote. | Apogee definitive proxy filed July 13, 2026 | August 3, 2026 |
| Merger approval and timing risk | The initial outside date is December 18, 2026, with an automatic six-month extension to June 18, 2027 and a second extension at Parent discretion if specified conditions are met. The agreement includes $381.3M company and reverse termination fees in specified circumstances, and AbbVie guarantees the payment obligations of Parent and Merger Sub. | Apogee definitive proxy | August 3, 2026 |
| Financial advisor valuation references | The proxy reports a Goldman Sachs implied equity value range of $126.05 to $149.30 per share using illustrative premiums, and a Jefferies discounted cash flow range of $98.90 to $119.20 per share, compared with the $135.11 merger consideration. These are advisor analyses, not guaranteed price floors. | Apogee definitive proxy | August 3, 2026 |
| Technical snapshot | 50-day SMA $112.77, 200-day SMA $82.93, RSI 78.56, 20-day average volume about 1.17M, and 52-week range $34.34 to $134.46 in the August 2 StockAnalysis snapshot. | StockAnalysis statistics and history | August 3, 2026 |
| Management and ownership | Michael Henderson is CEO. The definitive proxy lists 1,301,595 voting shares beneficially owned by all directors and executive officers, about 2.10% of voting shares as of the record date, and the supporting stockholders held about 3.3% of voting shares plus all non-voting shares. | Apogee definitive proxy | August 3, 2026 |
This APGE AI stock analysis page is an informational research tool only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are conditional scenarios based on available data as of August 3, 2026 and can be wrong if the AbbVie merger, the August 11 stockholder vote, regulatory review, clinical data, financing arrangements, or market conditions change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
